Novel Strategies To Boost Tristetraprolin Function: A Critical Anti-inflammatory Protein In Asthma
Funder
National Health and Medical Research Council
Funding Amount
$547,216.00
Summary
Asthma is a chronic disorder where airways are remodelled, resulting in poor lung function. Airway remodelling is a consequence of long-term inflammation. As current treatments halt some, but not all, aspects of airway remodelling, new therapeutic approaches are urgently required. In this grant, our aim is to devise novel strategies to boost the function of a critical anti-inflammatory protein - TTP - to reduce inflammation in asthma.
The Unstable, Rupture-prone Atherosclerotic Plaque: Innovative Methods For Its Detection And Stabilisation
Funder
National Health and Medical Research Council
Funding Amount
$748,447.00
Summary
Heart attacks and strokes are most often caused by rupture of unstable atherosclerotic plaques resulting in clotting and vessel occlusion and ultimately irreversible damage of the heart or brain. We have generated a mouse model that reproduces these plaques as seen in humans. Based on this model and human unstable plaques 1) we have discovered/developed imaging technologies that can identify these dangerous plaques and 2) we will develop drugs that prevent plaque rupture.
Inflammation And Oxidative Stress In Emerging Psychotic And Mood Disorders
Funder
National Health and Medical Research Council
Funding Amount
$432,619.00
Summary
We are conducting four large clinical trials testing anti-inflammatory treatments like ?-3 PUFAs and aspirin in young people who are at high-risk for psychosis or have depression. This proposal adds an important component to this research by investigating inflammatory and oxidative stress markers. We aim to determine if the investigated biomarkers predict the course of illness and response to treatments. The findings will facilitate early intervention and targeted treatment.
Activated Platelets As Unique Targets For Early Imaging And Site-directed Therapy Of Cardiovascular And Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$846,979.00
Summary
Heart attack and inflammatory diseases such as rheumatoid arthritis und multiple sclerosis either kill or severely disable people. We use the presence of platelets early on in these diseases to develop methods for early diagnosis as well as potential drugs for site-directed therapy. We have developed new biotechnological tools to perform novel high sensitivity imaging in Positron Emission Tomography (PET) and laser light imaging as well as a localised anti-inflammatory therapy.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes and Alzheimer’s. This project will reveal how the body deactivates inflammasomes - protein complexes at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation-driven disease.
Targeting Protease Activated Receptor 2 In Immunometabolism And Obesity
Funder
National Health and Medical Research Council
Funding Amount
$720,760.00
Summary
New approaches to prevent and treat obesity and metabolic diseases are National Health Priorities. Obesity is now recognised as an inflammatory disease. This project seeks new biomedical information to verify a new hypothesis that a protein (PAR2) on the surface of fat cells and immune cells is associated with the development of obesity and metabolic disorders.
The vision we rely on every day to read and recognise faces depends upon the health of the central portion of our retina, the macula. Age-related Macular Degeneration (AMD) is the leading cause of blindness in Australia and the western world. Researchers at the Australian National University are collaborating to bring a new test for AMD severity to the market within 3 years. The objective is to provide doctors with a rapid, cost-effective tool to help them manage treatment.
Nanoparticle And Virus Assisted Targeting Of MicroRNA And DNA For The Treatment Of Atherosclerosis, Myocardial Infarction And Other Inflammatory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$663,583.00
Summary
Inflammation is an underling cause or aggravating factor of many diseases, such as heart attack and atherosclerosis, but there is a lack of effective anti-inflammatory drugs that do not cause side effects. Using advanced biotechnology, we will use viruses and nanoparticles to selectively target gene therapeutics to areas of inflammation, resulting in high efficacy with low side effects. We will test these broadly usable therapeutics in mouse models of heart attack and atherosclerosis.
Can Esomeprazole Improve Outcomes In Women At High Risk Of Pre-eclampsia? A Phase II Placebo-controlled Randomised, Multi-centre Clinical Trial.
Funder
National Health and Medical Research Council
Funding Amount
$1,597,125.00
Summary
Pre-eclampsia, recognised through the development of high blood pressure in pregnancy, causes death and/or injury to mothers and babies. An improved understanding of the development of pre-eclampsia has provided opportunities for early prediction and prevention of disease. We will use a powerful predictive model to identify pregnancies at high risk of pre-eclampsia then observe the effect of a novel treatment (esomeprazole) on maternal blood pressure and the development of this disease.
Exploring And Targeting The Anti-Inflammatory Signalling Mechanisms Of Interleukin 37
Funder
National Health and Medical Research Council
Funding Amount
$1,018,306.00
Summary
Cytokines are messenger proteins that function as master regulators of biological processes; thus they play central roles in many diseases. The rare cytokines that block inflammation do so by dampening the immune system’s potentially destructive force, making them attractive targets for drug development. We showed that interleukin 37 is a powerful anti-inflammatory cytokine, and will now evaluate its mechanisms of action and its efficacy against several severe diseases, including cancer.